Evaluation and registration of adverse events in clinical drug trials in migraine

P. Tfelt-Hansen; N.H. Bjarnason; C. Dahlof; S. Derry; E. Loder; H. Massiou

Evaluation and registration of adverse events in clinical drug trials in migraine

P. Tfelt-Hansen, N.H. Bjarnason, C. Dahlof, S. Derry, E. Loder, H. Massiou

Institut for Klinisk Medicin

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

17 Citationer (Scopus)

Abstract

Tolerability of a drug should be regarded as important as its efficacy. In all four phases of drug development evaluation of adverse events is important. Recommendations for assessment of adverse events in acute and prophylactic clinical drug trials in migraine are given. Tolerability may be indirectly assessed using measures of general well-being and eight such tools are presented. Finally, recommendations for reporting of adverse events are given
Udgivelsesdato: 2008/7

Originalsprog	Engelsk
Tidsskrift	Cephalalgia
Vol/bind	28
Udgave nummer	7
Sider (fra-til)	683-688
Antal sider	5
ISSN	0333-1024
Status	Udgivet - 2008

Bibliografisk note

Times Cited: 0ReviewEnglishTfelt-Hansen, PUniv Copenhagen, Dept Neurol, Danish Headache Ctr, Glostrup Hosp, Copenhagen, DenmarkCited References Count: 24310NVBLACKWELL PUBLISHING9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLANDOXFORD

Citationsformater

@article{3b0a65d0064911deb05e000ea68e967b,

title = "Evaluation and registration of adverse events in clinical drug trials in migraine",

abstract = "Tolerability of a drug should be regarded as important as its efficacy. In all four phases of drug development evaluation of adverse events is important. Recommendations for assessment of adverse events in acute and prophylactic clinical drug trials in migraine are given. Tolerability may be indirectly assessed using measures of general well-being and eight such tools are presented. Finally, recommendations for reporting of adverse events are given Udgivelsesdato: 2008/7",

author = "P. Tfelt-Hansen and N.H. Bjarnason and C. Dahlof and S. Derry and E. Loder and H. Massiou",

note = "Times Cited: 0ReviewEnglishTfelt-Hansen, PUniv Copenhagen, Dept Neurol, Danish Headache Ctr, Glostrup Hosp, Copenhagen, DenmarkCited References Count: 24310NVBLACKWELL PUBLISHING9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLANDOXFORD",

year = "2008",

language = "English",

volume = "28",

pages = "683--688",

journal = "Cephalalgia",

issn = "0333-1024",

publisher = "SAGE Publications",

number = "7",

}

TY - JOUR

T1 - Evaluation and registration of adverse events in clinical drug trials in migraine

AU - Tfelt-Hansen, P.

AU - Bjarnason, N.H.

AU - Dahlof, C.

AU - Derry, S.

AU - Loder, E.

AU - Massiou, H.

N1 - Times Cited: 0ReviewEnglishTfelt-Hansen, PUniv Copenhagen, Dept Neurol, Danish Headache Ctr, Glostrup Hosp, Copenhagen, DenmarkCited References Count: 24310NVBLACKWELL PUBLISHING9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLANDOXFORD

PY - 2008

Y1 - 2008

N2 - Tolerability of a drug should be regarded as important as its efficacy. In all four phases of drug development evaluation of adverse events is important. Recommendations for assessment of adverse events in acute and prophylactic clinical drug trials in migraine are given. Tolerability may be indirectly assessed using measures of general well-being and eight such tools are presented. Finally, recommendations for reporting of adverse events are given Udgivelsesdato: 2008/7

AB - Tolerability of a drug should be regarded as important as its efficacy. In all four phases of drug development evaluation of adverse events is important. Recommendations for assessment of adverse events in acute and prophylactic clinical drug trials in migraine are given. Tolerability may be indirectly assessed using measures of general well-being and eight such tools are presented. Finally, recommendations for reporting of adverse events are given Udgivelsesdato: 2008/7

M3 - Journal article

SN - 0333-1024

VL - 28

SP - 683

EP - 688

JO - Cephalalgia

JF - Cephalalgia

IS - 7

ER -